REFERENCES:
1. Mills MC, Rahal C. The GWAS Diversity Monitor tracks diversity by
disease in real time. Nat Genet . 2020;52(3):242-243.
doi:10.1038/s41588-020-0580-y
2. Guerrero S, López-Cortés A, Indacochea A, et al. Analysis of
Racial/Ethnic Representation in Select Basic and Applied Cancer Research
Studies. Sci Rep . 2018;8(1):13978. doi:10.1038/s41598-018-32264-x
3. Caswell-Jin JL, Gupta T, Hall E, et al. Racial/ethnic differences in
multiple-gene sequencing results for hereditary cancer risk. Genet
Med Off J Am Coll Med Genet . 2018;20(2):234-239.
doi:10.1038/gim.2017.96
4. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical
use of current polygenic risk scores may exacerbate health disparities.Nat Genet . 2019;51(4):584-591. doi:10.1038/s41588-019-0379-x
5. U.S. Census Bureau QuickFacts: Bronxville village, New York; Bronx
County, New York. Accessed April 28, 2023.
https://www.census.gov/quickfacts/fact/table/bronxcountynewyork/PST045221
6. Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and Hereditary
Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics,
and Surveillance Recommendations in Childhood. Clin Cancer Res Off
J Am Assoc Cancer Res . 2017;23(12):e68-e75.
doi:10.1158/1078-0432.CCR-17-0547
7. Arunachalam AK, Maddali M, Aboobacker FN, et al. Primary
Immunodeficiencies in India: Molecular Diagnosis and the Role of
Next-Generation Sequencing. J Clin Immunol . 2021;41(2):393-413.
doi:10.1007/s10875-020-00923-2
8. VCV001343516.3 - ClinVar - NCBI. Accessed February 12, 2024.
https://www.ncbi.nlm.nih.gov/clinvar/variation/1343516/
9. Bu F, Borsa NG, Jones MB, et al. High-Throughput Genetic Testing for
Thrombotic Microangiopathies and C3 Glomerulopathies. J Am Soc
Nephrol JASN . 2016;27(4):1245-1253. doi:10.1681/ASN.2015040385
10. Kimble DC, Lach FP, Gregg SQ, et al. A comprehensive approach to
identification of pathogenic FANCA variants in Fanconi anemia patients
and their families. Hum Mutat . 2018;39(2):237-254.
doi:10.1002/humu.23366
11. Druker H, Zelley K, McGee RB, et al. Genetic Counselor
Recommendations for Cancer Predisposition Evaluation and Surveillance in
the Pediatric Oncology Patient. Clin Cancer Res Off J Am Assoc
Cancer Res . 2017;23(13):e91-e97. doi:10.1158/1078-0432.CCR-17-0834
12. Mersch J, Brown N, Pirzadeh-Miller S, et al. Prevalence of Variant
Reclassification Following Hereditary Cancer Genetic Testing.JAMA . 2018;320(12):1266-1274. doi:10.1001/jama.2018.13152
13. Richards CS, Bale S, Bellissimo DB, et al. ACMG recommendations for
standards for interpretation and reporting of sequence variations:
Revisions 2007. Genet Med . 2008;10(4):294-300.
doi:10.1097/GIM.0b013e31816b5cae